Insys Therapeutics (INSY) Tops Q4 EPS by 9c

Insys Therapeutics (NASDAQ: INSY) reported Q4 EPS of $0.53, $0.09 better than the analyst estimate of $0.44. Revenue for the quarter came in at $66.5 million versus the consensus estimate of $63.5 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15